Savara Inc. Reports Increased Loss Amid Ongoing R&D Investments

Savara ( (SVRA) ) has released its Q2 earnings. Here is a breakdown of the information Savara presented to its investors.

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, with its primary program being molgramostim inhalation solution for autoimmune pulmonary alveolar proteinosis. In its latest earnings report for the quarter ending June 30, 2025, Savara reported a net loss of $30.4 million, reflecting increased research and development expenses as the company continues to invest in its primary drug candidate. The company’s cash and cash equivalents stood at $17.4 million, with short-term investments totaling $129 million, indicating a strong liquidity position to support ongoing operations. Savara’s management remains focused on advancing its clinical trials and securing regulatory approvals, with plans to potentially raise additional capital to support future development and commercialization efforts.